ID

35327

Descrição

Study ID: 101222 Clinical Study ID: 101222 Study Title: Study to demonstrate the non-inferiority of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine compared to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine and to separate administration of DTPw-HBV Kft. and Hiberix™ vaccines with respect to the immunogenicity of all antigens, when administered to healthy infants. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT) Trade Name:Zilbrix/Hib Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Palavras-chave

Versões (2)
  1. 25/02/2019 25/02/2019 -
  2. 28/02/2019 28/02/2019 -
Titular dos direitos

GSK group of companies

Transferido a

28 de fevereiro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Immunogenicity of TPw-HBV/Hib Kft. Vaccine in healthy infants - 101222

Inglês

Visit 1

1 Formulários  
  1. StudyEvent: ODM
    1. Visit 1
Administrative data
Descrição

Administrative data

Visit Number
Descrição

Visit Number

Tipo de dados

integer

Subject Number
Descrição

Subject Number

Tipo de dados

integer

ELIMINATION CRITERIA
Descrição

ELIMINATION CRITERIA

Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of the combined DTPw-HepB vaccine or DTPw-HepB/Hib vaccine, with the exception of oral poliovirus vaccine (OPV).
Descrição

The following criteria should be checked at Visit 2. If any become applicable during the study, it will not require withdrawal of the subject from the study but does determine a subject’s evaluability in the according-to-protocol analysis (ATP) analysis

Tipo de dados

boolean

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
Descrição

EliminationCriteriaConcomitantMedication

Tipo de dados

boolean

Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
Descrição

EliminationCriteriaImmunosuppressants

Tipo de dados

boolean

Hepatitis B vaccine received after the first 72 hours of life.
Descrição

EliminationCriteriaPriorVaccination

Tipo de dados

boolean

Bacille Calmette-Guérin (BCG) vaccine given after the first 2 weeks of life.
Descrição

EliminationCriteriaBacilleCalmette-Guérin

Tipo de dados

boolean

Previous vaccination against diphtheria, tetanus, pertussis or Haemophilus influenzae or hepatitis B (except if indicated in the group allocation).
Descrição

EliminationCriteriaPreviousVaccination

Tipo de dados

boolean

History of or known exposure to diphtheria, tetanus, pertussis, hepatitis B or Hib diseases.
Descrição

EliminationCriteriaHistoryDiphteria

Tipo de dados

boolean

Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing is required at study entry).
Descrição

EliminationCriteriaImmunodeficientCondition

Tipo de dados

boolean

History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
Descrição

EliminationCriteriaAllergies

Tipo de dados

boolean

Administration of immunoglobulins and/ or any blood products during the study period.
Descrição

EliminationCriteriaImmunoglobulinsAdministration

Tipo de dados

boolean

Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period.
Descrição

The following criteria should be checked at Visits 3, 4 and 5. If any become applicable during the study, it will not require withdrawal of the subject from the study but does determine a subject’s evaluability in ATP analysis.

Tipo de dados

boolean

Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
Descrição

EliminationCriteriaChronicImmunosuppressantsAdministration

Tipo de dados

boolean

Planned administration/ administration of a vaccine not foreseen by the study protocol during the period from 30 days before each dose of vaccine and ending 30 after the last dose of vaccine, with the exception of OPV.
Descrição

EliminationCriteriaPlannedConcomitantVaccineAdministration

Tipo de dados

boolean

Administration of immunoglobulins and/or any blood products during the study period.
Descrição

EliminationCriteriaImmunoglobulinsAdministration

Tipo de dados

boolean

Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing required at study entry).
Descrição

EliminationCriteriaImmunodeficientCondition

Tipo de dados

boolean

CONTRAINDICATIONS TO SUBSEQUENT VACCINATION
Descrição

CONTRAINDICATIONS TO SUBSEQUENT VACCINATION

Anaphylactic reaction following the administration of vaccines.
Descrição

The following adverse events (AEs) constitute absolute contraindications to further administration of the study vaccines; if any of these AEs occur during the study, the subject must not receive additional doses of vaccine but may continue other study procedures at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE

Tipo de dados

boolean

Known hypersensitivity to any component of the vaccine, or subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B or Hib vaccines
Descrição

ContraindicationsHypersensitivity

Tipo de dados

boolean

Encephalopathy (not due to another identifiable cause).
Descrição

This is defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination, and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours. Even though causation by DTP vaccine cannot be established, no subsequent doses of pertussis vaccine should be given. In these circumstances the vaccination course should be continued with DT and HB vaccines.

Tipo de dados

boolean

Acute disease at the time of vaccination. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature < 37.5 °C or rectal temperature < 38 °C.
Descrição

The following AEs constitute contraindications to administration of the study vaccines at that point in time; if any one of these AEs occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE.

Tipo de dados

boolean

Axillary or oral temperature = 37.5 °C or Rectal temperature = 38 °C at the time of vaccination.
Descrição

ContraindicationsTemperature

Tipo de dados

boolean

Precautions:
Descrição

Precautions:

Fever = 40.0 °C (preferable axillary temperature or oral temperature) within 48 hours of vaccination, not due to another identifiable cause.
Descrição

If any of the following events occur in temporal relation to receipt of study vaccines, the decision to give subsequent doses of vaccine containing the pertussis component should be carefully considered.

Tipo de dados

boolean

Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
Descrição

PrecautionsShock

Tipo de dados

boolean

Persistent crying lasting = 3 hours, occurring within 48 hours of vaccination
Descrição

PrecautionsCrying

Tipo de dados

boolean

Convulsions with or without fever, occurring within 3 days of vaccination.
Descrição

PrecautionsConvulsions

Tipo de dados

boolean

Additional Precautions:
Descrição

AdditionalPrecautions

Tipo de dados

text

INFORMED CONSENT
Descrição

INFORMED CONSENT

I certify that Informed Consent has been obtained prior to any study procedure.
Descrição

I certify that Informed Consent has been obtained prior to any study procedure.

Tipo de dados

boolean

Informed Consent Date :
Descrição

Informed Consent Date :

Tipo de dados

date

DEMOGRAPHICS
Descrição

DEMOGRAPHICS

Center number :
Descrição

CenterNumber

Tipo de dados

integer

Date of birth :
Descrição

BirthDate

Tipo de dados

date

Gender :
Descrição

Gender :

Tipo de dados

text

Race :
Descrição

Race

Tipo de dados

text

If Other, please specify
Descrição

OtherRace

Tipo de dados

text

ELIGIBILITY CHECK
Descrição

ELIGIBILITY CHECK

Did the subject meet all the entry criteria?
Descrição

Do not enter the subject into the study if he/she failed any inclusion or exclusion criteria below.

Tipo de dados

boolean

INCLUSION CRITERIA
Descrição

INCLUSION CRITERIA

Tick the boxes corresponding to any of the inclusion criteria the subject failed
Descrição

InclusionCriteriaFailed

Tipo de dados

text

EXCLUSION CRITERIA
Descrição

EXCLUSION CRITERIA

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.
Descrição

ExclusionCriteria

Tipo de dados

text

RANDOMISATION / TREATMENT ALLOCATION
Descrição

RANDOMISATION / TREATMENT ALLOCATION

Record treatment number
Descrição

TreatmentNumber

Tipo de dados

integer

GROUP HBV AT BIRTH
Descrição

GROUP HBV AT BIRTH

Has the Engerix™-B vaccine been administered at birth ?
Descrição

ENGERIX™-B VACCINE Only for subjects in the HBV+DTPw-HBV/Hib Kft group

Tipo de dados

boolean

Voltar ao início da página

Similar models

Visit 1

1 Formulários
  1. StudyEvent: ODM
    1. Visit 1
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Administrative data
Visit Number
Item
Visit Number
integer
Subject Number
Item
Subject Number
integer
Item Group
ELIMINATION CRITERIA
Planned administration/administration of a vaccine not foreseen by the study protocol
Item
Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of the combined DTPw-HepB vaccine or DTPw-HepB/Hib vaccine, with the exception of oral poliovirus vaccine (OPV).
boolean
EliminationCriteriaConcomitantMedication
Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
boolean
EliminationCriteriaImmunosuppressants
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
boolean
EliminationCriteriaPriorVaccination
Item
Hepatitis B vaccine received after the first 72 hours of life.
boolean
EliminationCriteriaBacilleCalmette-Guérin
Item
Bacille Calmette-Guérin (BCG) vaccine given after the first 2 weeks of life.
boolean
EliminationCriteriaPreviousVaccination
Item
Previous vaccination against diphtheria, tetanus, pertussis or Haemophilus influenzae or hepatitis B (except if indicated in the group allocation).
boolean
EliminationCriteriaHistoryDiphteria
Item
History of or known exposure to diphtheria, tetanus, pertussis, hepatitis B or Hib diseases.
boolean
EliminationCriteriaImmunodeficientCondition
Item
Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing is required at study entry).
boolean
EliminationCriteriaAllergies
Item
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
boolean
EliminationCriteriaImmunoglobulinsAdministration
Item
Administration of immunoglobulins and/ or any blood products during the study period.
boolean
EliminationCriteriaConcomitantVaccines
Item
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period.
boolean
EliminationCriteriaChronicImmunosuppressantsAdministration
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
boolean
EliminationCriteriaPlannedConcomitantVaccineAdministration
Item
Planned administration/ administration of a vaccine not foreseen by the study protocol during the period from 30 days before each dose of vaccine and ending 30 after the last dose of vaccine, with the exception of OPV.
boolean
EliminationCriteriaImmunoglobulinsAdministration
Item
Administration of immunoglobulins and/or any blood products during the study period.
boolean
EliminationCriteriaImmunodeficientCondition
Item
Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing required at study entry).
boolean
Item Group
CONTRAINDICATIONS TO SUBSEQUENT VACCINATION
ContraindicationsAnaphylacticReaction
Item
Anaphylactic reaction following the administration of vaccines.
boolean
ContraindicationsHypersensitivity
Item
Known hypersensitivity to any component of the vaccine, or subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B or Hib vaccines
boolean
ContraindicationsEncephalopathy
Item
Encephalopathy (not due to another identifiable cause).
boolean
ContraindicationsDisease
Item
Acute disease at the time of vaccination. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature < 37.5 °C or rectal temperature < 38 °C.
boolean
ContraindicationsTemperature
Item
Axillary or oral temperature = 37.5 °C or Rectal temperature = 38 °C at the time of vaccination.
boolean
Item Group
Precautions:
PrecautionsFever
Item
Fever = 40.0 °C (preferable axillary temperature or oral temperature) within 48 hours of vaccination, not due to another identifiable cause.
boolean
PrecautionsShock
Item
Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
boolean
PrecautionsCrying
Item
Persistent crying lasting = 3 hours, occurring within 48 hours of vaccination
boolean
PrecautionsConvulsions
Item
Convulsions with or without fever, occurring within 3 days of vaccination.
boolean
Item
Additional Precautions:
text
AdditionalPrecautions
Code List
Additional Precautions:
CL Item
A history of febrile convulsions, a family history of convulsions, a family history of Sudden Infant Death (1)
CL Item
Syndrome (SIDS) and a family history of an adverse event following Tritanrix™-HepB vaccination do not (Syndrome (SIDS) and a family history of an adverse event following Tritanrix™-HepB vaccination do not)
CL Item
constitute contraindications. (constitute contraindications.)
CL Item
As with all injectable vaccines, appropriate medical treatment should always be readily available in case of (2)
CL Item
anaphylactic reactions following the administration of the vaccine. For this reason, the vaccinee should (anaphylactic reactions following the administration of the vaccine. For this reason, the vaccinee should)
CL Item
remain under medical supervision for 30 minutes after vaccination. (remain under medical supervision for 30 minutes after vaccination.)
CL Item
DTPw-HBV should be administered with caution to subjects with thrombocytopenia or a bleeding disorder (3)
CL Item
since bleeding may occur following an intramuscular administration to these subjects. (since bleeding may occur following an intramuscular administration to these subjects.)
CL Item
DTPw-HBV should under no circumstances be administered intravenously. (DTPw-HBV should under no circumstances be administered intravenously.)
Item Group
INFORMED CONSENT
I certify that Informed Consent has been obtained prior to any study procedure.
Item
I certify that Informed Consent has been obtained prior to any study procedure.
boolean
Informed Consent Date :
Item
Informed Consent Date :
date
Item Group
DEMOGRAPHICS
CenterNumber
Item
Center number :
integer
BirthDate
Item
Date of birth :
date
Item
Gender :
text
Gender :
Code List
Gender :
CL Item
Male (1)
CL Item
Female (2)
Item
Race :
text
Race
Code List
Race :
CL Item
Black (1)
CL Item
Arabic/North African (2)
CL Item
White/Caucasian (3)
CL Item
East & South East Asian (4)
CL Item
South Asian (5)
CL Item
American Hispanic (6)
CL Item
Japanese (7)
CL Item
Other (8)
OtherRace
Item
If Other, please specify
text
Item Group
ELIGIBILITY CHECK
EligibilityCheckQuestion
Item
Did the subject meet all the entry criteria?
boolean
Item Group
INCLUSION CRITERIA
Item
Tick the boxes corresponding to any of the inclusion criteria the subject failed
text
InclusionCriteriaFailed
Code List
Tick the boxes corresponding to any of the inclusion criteria the subject failed
CL Item
Born to a mother known to be seronegative for HBsAg (documented laboratory result of HBsAgassay from a maternal blood sample is available). (1)
CL Item
Written informed consent obtained from the parent or guardian of the subject. (2)
CL Item
Free of obvious health problems as established by medical history and clinical examination (3)
CL Item
before entering into the study. (before entering into the study.)
CL Item
Born after a normal gestation period (between 36 and 42 weeks). (4)
CL Item
A male or female less than or equal to 3 days (72 hours) of age at the time of the birth dose of (5)
CL Item
Hepatitis B vaccination, if indicated for the group. (Hepatitis B vaccination, if indicated for the group.)
CL Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) since birth, or planned use during the study period. (6)
Item Group
EXCLUSION CRITERIA
Item
Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.
text
ExclusionCriteria
Code List
Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.
CL Item
Use of any investigational or non-registered product (drug or vaccine) other than the study (1)
CL Item
vaccine(s) since birth, or planned use during the study period. (vaccine(s) since birth, or planned use during the study period.)
CL Item
Any confirmed immunodeficient condition, based on medical history and physical (2)
CL Item
examination (no laboratory testing is required at study entry). (examination (no laboratory testing is required at study entry).)
CL Item
A family history of congenital or hereditary immunodeficiency. (3)
CL Item
Major congenital defects or serious chronic illness. (4)
CL Item
History of any neurologic disorders or seizures. (5)
CL Item
Administration of immunoglobulins and/or any blood products since birth or planned (6)
CL Item
administration during the study period. (administration during the study period.)
CL Item
Acute disease at the time of enrolment. (Acute disease is defined as the presence of a (7)
CL Item
moderate or severe illness with or without fever. All vaccines can be administered to (moderate or severe illness with or without fever. All vaccines can be administered to)
CL Item
persons with a minor illness such as diarrhea, mild upper respiratory infection with or without (persons with a minor illness such as diarrhea, mild upper respiratory infection with or without)
CL Item
low-grade febrile illness, i.e., axillary temperature < 37.5 °C or rectal temperature < 38 °C). (low-grade febrile illness, i.e., axillary temperature < 37.5 °C or rectal temperature < 38 °C).)
CL Item
Other conditions which in the opinion of the investigator may potentially interfere with (8)
CL Item
interpretation of study outcomes. (interpretation of study outcomes.)
CL Item
Hepatitis B vaccination given at birth outside the study. (9)
Item Group
RANDOMISATION / TREATMENT ALLOCATION
TreatmentNumber
Item
Record treatment number
integer
Item Group
GROUP HBV AT BIRTH
VaccinationAtBirth
Item
Has the Engerix™-B vaccine been administered at birth ?
boolean
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial